Health Condition 1: B354- Tinea corporis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: All patients above the age of 18 years of either sex who were clinically and mycologically diagnosed of a case of localized dermatophytosis were included in the study.
Exclusion criteria
Exclusion criteria: Patients with extensive dermatophytosis, other forms of tinea infections Superadded bacterial infection Immunocompromised patients Dermatitis such as contact dermatitis, atopic dermatitis, psoriasis, other skin diseases Use of corticosteroids in the last 4 weeks. Pregnant and lactating mothers Patients with a history of hypersensitivity to azole antifungals Patients who received topical antifungal within 1 week before baseline visit and patients who received systemic antifungals within 4 weeks before baseline were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was to determine the efficacy and safety of two topical {naftifine, luliconazole} therapies in terms of a number of patients achieving complete clearance.Timepoint: The primary outcome was to determine the efficacy and safety of two topical {naftifine, luliconazole} therapies in terms of a number of patients achieving complete clearance at 2 weeks, 4 weeks, 6 weeks , 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome was to determine the safety of two topical {naftifine, luliconazole} therapies in terms of number of patients achieving complete clearance.Timepoint: The secondary outcome was to determine the safety of two topical {naftifine, luliconazole} therapies in terms of number of patients achieving complete clearance at 2 weeks, 4 weeks, 6 weeks & 8 weeks | — |
Countries
India
Contacts
KARPAGA VINAYAGA INSTITUTE OF MEDICAL SCIENCES AND RESEARCH CENTRE